Rodman & Renshaw Global Healthcare Conference 2007 takes place May
14 - 15, 2007 at the Le Meridien Beach Plaza Hotel in Monte Carlo,
Monaco. For in-depth information about the event, visit
http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf20.
Listed below are Rodman & Renshaw Global Healthcare Conference
2007 presenter profiles. Business Wire is the official news wire for
the Rodman & Renshaw Global Healthcare Conference. Breaking news
releases are available at Tradeshownews.com, Business Wire's trade
show, conference, and event news resource.
-0-
*T
Company: Accentia Biopharmaceuticals, Inc.
Ticker Symbol & Exchange: NASDAQ: ABPI
Investor Relations Contact: Adam S. Holdsworth, 212-825-3210
Web: www.accentia.net
Date of Presentation: 5/14/2007
Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company
focused on the development of late-stage "disruptive" clinical
products, especially for already-approved drugs in new formulations
and/or new indications that are patent-protected and which represent
new therapeutics with greater clinical and economic value. Accentia
has a pipeline of products in late-stage clinical development. The
company's lead respiratory product candidate is SinuNase(TM), which
is under clinical development to treat chronic sinusitis
(rhinosinusitis). SinuNase is a novel application and formulation of
a known anti-fungal exclusively licensed from the Mayo Foundation for
Medical Education and Research. The product has been Fast Tracked by
the FDA and the Company has commenced a Phase 3 clinical trial. The
Company's other lead product is BiovaxID(TM), a patient-specific
anti-cancer vaccine for the treatment of follicular non-Hodgkin's
lymphoma. BiovaxID, which is being developed by Accentia's
subsidiary, Biovest International, Inc. (OTCBB: BVTI), is currently
in a Fast-Tracked Phase 3 clinical trial. Through Biovest, the
Company also manufactures AutovaxID(TM), an FDA approved commercial-
stage automated cell-manufacturing device that enables the cost-
effective and scalable production of proteins and other cell-based
products. Accentia is also proposing to enter a Phase 3 clinical
trial for Multiple Sclerosis using Revimmune(TM), which uses an
approved drug in an exclusively licensed method of therapy to
"reboot" a patient's immune system. Revimmune was developed at the
Johns Hopkins School of Medicine for the elimination of autoimmunity,
and Accentia has acquired the exclusive worldwide rights for all
autoimmune diseases. For further information, please visit
www.accentia.net.
Company: Accera, Inc.
Investor Relations Contact: Meghan Feeks, Richard Lewis
Communications, Inc., 212.827.0020
Web: www.accerapharma.com
Date of Presentation: Tuesday, May 15, 11:30 a.m.
Accera, Inc. is a private biopharmaceutical company focused on the
discovery and development of novel therapeutics for neurodegenerative
diseases. Based on a deep understanding of the neuronal metabolism
defects commonly observed in CNS diseases, Accera's proprietary
neuron energetics technology platform is being used to develop drugs
in multiple indications including Alzheimer's disease, age-associated
memory impairment, Parkinson's disease, and canine cognitive
dysfunction. Through its own small molecule discovery program, in-
licensing, and the acquisition of clinical compounds with
demonstrated safety and efficacy, Accera continues to build a strong
and diversified product pipeline.
Company: Altegen, Inc
Investor Relations Contact: Martin Atterby, 49 172 4583865 / 49 172
4583866
Web: www.altegen.com
Date of Presentation: 15.05.2007
Altegen has developed "samfor" blood tests for the pre-symptomatic /
symptomatic diagnosis of major human diseases. "Samforad" detects
expression of an AD-specific Beta-amyloid precursor protein "ALZAS"
(protein and RNA) and an anti-ALZAS auto-antibody. Anti-ALZAS/ALZAS
blood levels enable determination of staging of AD and probably of
the efficacy of therapeutic treatments. Launch for Samforad is
September 2007. Anti-ALZAS vaccine clinical trial phases I/II starts
February 2008. "Samformad" screens human blood for BSE by detecting
"Prionins." Ready-for-use-PrPSc is produced in minutes by converting
in vitro (in test tubes) all species of native or recombinant PrP
using prionins. European patents have been granted.
Company: Alteon Inc
Ticker Symbol & Exchange: ALT
Investor Relations Contact: Noah Berkowitz, 201 818 5877
Web: www.alteon.com
Date of Presentation: 14-May-07
Alteon is a product-based biopharmaceutical company engaged in the
development of drugs to treat and prevent cardiovascular diseases,
particularly among patients with diabetes.
ALT-2074, is a glutathione peroxidase mimetic shown to protect
myocardium in preclinical models of heart attack. The drug is in
clinical development for reducing the morbidity and mortality
following MI, in patients with diabetes and a variant of an high risk
biomarker called haptoglobin. Alagebrium chloride is an Advanced
Glycation End-product Crosslink Breaker being developed for diastolic
heart failure and nephropathy. These diseases represent a rapidly
growing market of unmet medical need, particularly common among
diabetic patients.
Company: Aus Bio Limited
Investor Relations Contact: Dr Peter Jenkins - Executive Director,
(61) 411 88 46 42
Web: www.ausbio.com.au
Date of Presentation: 14th May, 2007 0820 hrs. - Zephyr Salon
AusBio is a medicinal biochemistry company. By linking the discipline
of molecular medicine, new drug candidates have been created, for
disease states, which are large and require new therapeutics. The
Company's principal scientists have a proven track record of
international commercial success following innovative R & D.
Principal projects include diabetes mellitus, chronic wound healing,
chronic hepatitis B & C, immune modulators and acute/chronic
respiratory conditions. Lead candidate selection and Proof of Concept
has occurred with the diabetes and wound healing projects, the latter
now entering a Phase II study. All I.P. created in house and owned
outright.
Company: Avalon Pharmaceuticals, Inc.
Ticker Symbol & Exchange: NASDAQ: AVRX
Investor Relations Contact: David M. Muth, 301-556-9900 (U.S.)
Web: Avalonrx.com
Date of Presentation: Monday, May 14, at 3:15 p.m. CEST (Central
European Summer Time), 9:15 a.m. EDT
(Eastern Daylight Time).
Avalon Pharmaceuticals is a biopharmaceutical company focused on the
discovery and development of potential first-in-class cancer
therapeutics. Avalon has a lead product in Phase I clinical
development (AVN944), preclinical programs to develop inhibitors for
the Beta-catenin and Aurora pathways, discovery programs for Survivin
and Myc pathway inhibitors, and value generating partnerships with
Merck, MedImmune, Medarex, and Novartis. By utilizing AvalonRx(R) our
platform technology, based upon the proprietary use of large-scale
gene expressions, we are uniquely positioned to develop therapeutics
focused on pathways that have historically been characterized as
"undruggable." Avalon was established in 1999 and is headquartered in
Germantown, Maryland.
Company: Axcan Pharma Inc.
Ticker Symbol & Exchange: NASDAQ Global Market: AXCA / Toronto Stock
Exchange: AXP
Investor Relations Contact: Isabelle Adjahi, 450-467-2600 ext. 2000
(Canada)
Web: www.axcan.com
Date of Presentation: 5/15/2007
Axcan is a leading multinational specialty pharmaceutical company
focused on gastroenterology. The company develops and markets a broad
line of prescription products to treat a range of gastrointestinal
diseases and disorders such as inflammatory bowel disease, irritable
bowel syndrome, cholestatic liver diseases and complications related
to pancreatic insufficiency. Axcan's products are marketed by its own
specialized sales forces in North America and Europe.
Company: BioLineRx Ltd.
Ticker Symbol & Exchange: Tel Aviv: BLRX
Investor Relations Contact: Yuri Shoshan, VP Finance and Corporate
Development, 972-2-548-9100
Email: yuri@biolinerx.com
Web: www.biolinerx.com
Date of Presentation: May 14, 2007, 4:40 PM ET
BioLineRx is Israel's leading drug development company. Partnering
with researchers, universities and biotech companies, BioLineRx
advances projects from early stage discovery and lead generation to
advanced clinical trials, regulatory approval and marketing. The
Company was founded in 2003 by leaders in the Israeli life science
arena including Teva Pharmaceuticals Ltd., venture capital firms
Giza, Pitango and Hadasit, the technology transfer company of
Hadassah hospital.
The Company's leading programs are for the treatment of schizophrenia
and damaged heart tissue post-myocardial infarction. Additional
products under development include compounds for the treatment of
cancer and CNS, cardiovascular, metabolic, infectious and autoimmune
diseases.
Company: Bionovo, Inc
Ticker Symbol & Exchange: BNVI
Investor Relations Contact: Jim Stapleton, jim@bionovo.com;
510.601.2000
Web: www.bionovo.com
Date of Presentation: Mon. May 14th 8:40am
Bionovo (BNVI) is a publicly traded pharmaceutical company focused on
discovering and developing drugs for women's health and cancer.
Bionovo is a leader in systems-biology integration with candidates
designed to address specific targets associated with the regulation
of pathological conditions. The company is working simultaneously on
two distinct discovery approaches, one focusing on pro-apoptotic
agents for cancer and a second, in the area of selective estrogen
receptor modulators (SERMS) to treat severe menopausal symptoms. Both
approaches are highly selective to yield products that will
effectively and safely address these areas of high unmet need. The
company's clinical development strategy leverages relationships with
key faculty at leading research institutions to conduct trials with
recognized opinion leaders.
Company: BioSante Pharmaceuticals, Inc.
Ticker Symbol & Exchange: Amex: BPA
Investor Relations Contact: Phillip Donenberg, 847-478-0500 ext 101
Web: www.biosantepharma.com
Date of Presentation: 14-May-07
BioSante is developing a pipeline of hormone therapy products to treat
both men and women. BioSante's lead products include Elestrin(TM)
(estradiol gel), developed through FDA approval by BioSante,
indicated for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause, and LibiGel(R) (transdermal testosterone
gel) in Phase III development for the treatment of female sexual
dysfunction (FSD). The company also is developing its calcium
phosphate nanotechnology (CaP) for novel vaccines, including
hepatitis B, avian flu and biodefense vaccines for toxins such as
anthrax, as well as a system for delivering drugs via alternative
routes of administration.
Company: DOV Pharmaceutical, Inc.
Ticker Symbol & Exchange: DOVP.PK (Pink Sheets)
Investor Relations Contact: Matthew Moore, 732-907-3667
Web: www.dovpharm.com
Date of Presentation: Tuesday, May 15, 2007
DOV is a biopharmaceutical company focused on the discovery,
acquisition and development of novel drug candidates for CNS
disorders. We have active drug development programs that are at the
preclinical, Phase I and Phase II clinical stages, including DOV
21,947 (entering Phase II for depression), DOV 102,677 (Phase I for
alcohol abuse) and an active preclinical discovery program in
reuptake inhibitors and GABA modulators. We have entered into a
sublicensing agreement with Neurocrine Biosciences, for indiplon for
the treatment of insomnia and with XTL Development, for bicifadine
for the treatment of pain. We are seeking a partner for DOV diltiazem
for the treatment of angina and hypertension.
Company: DURECT Corporation
Ticker Symbol & Exchange: DRRX; Nasdaq
Investor Relations Contact: Matthew J. Hogan, 408-777-4936
Web: www.durect.com
Date of Presentation: 14-May-07
DURECT Corporation is an emerging specialty pharmaceutical company
developing pharmaceutical systems based on its proprietary drug
delivery platform technologies. The Company currently has a number of
late-stage pharmaceutical products in development addressing large
markets in pain management, with a number of research programs
underway targeting chronic disease and other therapeutic areas. For
more information, please visit www.durect.com.
Company: EntreMed, Inc.
Ticker Symbol & Exchange: ENMD
Investor Relations Contact: Ginny Dunn, 240-864-2643
Web: www.entremed.com
Date of Presentation: Monday, May 14, 2007
EntreMed, Inc. is a clinical-stage pharmaceutical company focused on
developing multi-mechanism oncology drugs that target disease cells
directly and the blood vessels that nourish them.
EntreMed's goal is to develop and commercialize therapeutics based on
the Company's scientific expertise in angiogenesis, cell cycle
regulation and inflammation -- processes vital to the progression of
cancer and other diseases. The Company's three clinical product
candidates are based on these mechanisms. The Company's expertise has
also led to the identification of new molecules, including new
chemical entities derived from 2ME2, as well as new chemical entities
associated with multi-kinase inhibition and HDAC inhibition,
important targets in the treatment of oncology.
Company: Evotec AG
Ticker Symbol & Exchange: FSE: EVT
Investor Relations Contact: Anne Hennecke, 49-40-56081-286
Web: anne.hennecke@evotec.com
Date of Presentation: 14 May 2007, 05.20 pm
Evotec is a leader in the discovery and development of novel small
molecule drugs.
In proprietary projects, Evotec specialises in finding new treatments
for diseases of the central nervous system. Evotec has three
programmes in clinical development: EVT 201 (GABAA modulator) for the
treatment of insomnia, EVT 101 (NMDA NR2B subtype antagonist) for the
treatment of Alzheimer's disease/pain and EVT 302 (MAO-B inhibitor)
in development for smoking cessation.
In contract research, Evotec has established itself as the partner of
choice for pharmaceutical and biotechnology companies worldwide. The
Company provides innovative and often integrated solutions from drug
target to clinic through an unmatched range of capabilities,
including early stage assay development/screening through to
medicinal chemistry and drug manufacturing.
Company: GammaCan International Inc.
Ticker Symbol & Exchange: OTC BB: GCAN
Investor Relations Contact: Yaron Cherny, 972 3 738 2616 / 972 54 399
1313
Web: www.GammaCan.com
Date of Presentation: May 14th
GammaCan (OTCBB: GCAN) develops immunotherapies to treat cancer.
VitiGam(TM) is GammaCan's lead program in development for the
treatment of stage III and stage IV melanoma. Based on having
demonstrated potent anti-melanoma activity in animal models,
VitiGam(TM) is expected to enter Phase I/II trials under an U.S. IND
in 2008. VitGam(TM) is an IgG-based product manufactured from plasma
of donors with vitiligo, a benign skin condition. GammaCan owns U.S.
patents covering uses of IgG to treat cancer and vitiligo-derived IgG
(VitiGam(TM)) to treat melanoma. GammaCan has additional pending
patent applications covering IgG-based therapies. GammaCan is located
in Israel and the U.S.
Company: Genetic Immunity
Investor Relations Contact: Dr. Julianna Lisziewicz, 36-30-550-5596
Web: www.geneticimmunity.com
Date of Presentation: May 14, from 12:15 to 12:35 PM Zephyr
Salon
Genetic Immunity, a US-Hungarian biopharmaceutical enterprise, is a
leader in the development of proprietary DNA nanoparticle-based
topical cellular vaccines. The lead product, DermaVir Patch for the
treatment of HIV/AIDS, has been demonstrated safe and effective in
NIH sponsored primate studies. A Phase I clinical trial demonstrated
safety and long-lived cellular immunogenicity in HIV-infected
individuals. NIH and Karolinska Institute sponsored Phase II trials
are underway in the US and EU. Product pipeline based on the
Company's patented platform technology is under development through
the Vaccine Therapy Cluster (www.vaccinetherapy.eu).
Company: GENFIT
Ticker Symbol & Exchange: ALGFT
Investor Relations Contact: Guillaume LOHR, 33 (0)6 07 34 14 77,
Guillaume.lohr@genfit.com
Date of Presentation: 5/14/2007
Genfit is an innovative biopharmaceutical company, enabling and
developing 'first in class' or 'best to market' medicines for the
prevention and treatment of cardiometabolic disease, the leading
cause of mortality in the world.
Located in Lille, (France) and Cambridge (MA, USA), Genfit scientific
foundations are based on the renown expertise of Prof. Jean-Charles
Fruchart and Prof Bart Staels, and has been managed from inception by
Mr Jean-Francois Mouney, combining many years of experience in both
business and science. Genfit nurtures innovative drug research in an
advanced scientific environment, with clinical output as the key
permanent objective.
Genfit's mission is to discover and develop innovative new chemical
entities targeting metabolic diseases, inflammatory disorders, and
more generally cardiometabolic risk factors (dyslipidemia,
atherosclerosis, diabetes, obesity, hypertension, neurodegenerative
diseases...): Our aim is to improve the care of patients by
researching and developing today, better and safer treatments for the
future either based on new therapeutic targets (with a strong focus
on nuclear receptors), or on a "multimodal drug discovery approach",
targeting several indications simultaneously.
With a unique partnering track-record, Genfit recognizes that
pharmaceutical R&D needs multiple types of expertise and resources,
and our company culture values alliances with leading international
pharmaceutical groups, at different stages on the drug discovery and
development value chain.
Company: Glycadia Pharmaceuticals
Investor Relations Contact: Perry M. Cohen, (215) 557-8021
Web: Glycadia.com
Date of Presentation: 5/14/2007
Glycadia is developing drugs to treat kidney, eye and cardiovascular
complications of diabetes. These innovative and proprietary therapies
target upstream diabetes-specific abnormalities contributory to these
disorders that result from diabetes.
The prevalence of diabetes and its complications has reached epidemic
proportions. There are no drugs available that directly target
diabetes-specific abnormalities underlying the microvascular and
macrovascular diseases associated with diabetes.
Glycadia's lead candidate, GLY-230, an orally active small molecule,
is in clinical trials for diabetic nephropathy. Submission of Phase
2b protocols is expected in the second half of 2007.
Company: Hollis-Eden Pharmaceuticals, Inc.
Ticker Symbol & Exchange: NASDAQ: HEPH
Investor Relations Contact: Scott A. Rieger, 858-587-9333
Web: www.holliseden.com
Date of Presentation: 15-May-07
Hollis-Eden Pharmaceuticals is the world leader in the development of
a proprietary class of small molecule compounds that are metabolites
or synthetic analogs of endogenous adrenal steroid hormones. The
Company's clinical drug development candidates include HE3286, a
next-generation compound being prepared for clinical trials in
treating type 2 diabetes and potentially rheumatoid arthritis, and
HE3235, selected for clinical development in cancer. In addition,
Hollis-Eden has an active research program that is generating
additional new clinical leads that are being further evaluated in
preclinical models of a number of different diseases.
Company: Hunter-Fleming Ltd
Investor Relations Contact: Dr Michael Capaldi, 44 117 900 8265
Web: www.hunter-fleming.com
Date of Presentation: Tuesday 15th May
Dr Mike Capaldi, CEO of Hunter-Fleming Ltd. will be presenting the
latest developments at the UK based biopharmaceutical company to the
Rodman & Renshaw Global Healthcare Conference on 15th May 2007.
Hunter-Fleming specializes in the development of innovative medicines
to treat inflammatory degenerative diseases. The Company's lead
product is currently in phase II clinical development for Alzheimer's
disease. Two further products are in phase I clinical development
with a further compound series in lead optimization. A fifth product
for asthma and other autoimmune diseases has been out-licensed to
Trident Pharmaceuticals and will enter pre-clinical toxicology during
2007.
Company: ImClone Systems Incorporated
Ticker Symbol & Exchange: IMCL
Investor Relations Contact: Rebecca Gregory, 646-638-5058
Web: www.imclone.com
Date of Presentation: Monday, May 14, 2007
ImClone Systems Incorporated is committed to advancing oncology care
by developing a portfolio of targeted biologic treatments designed to
address the medical needs of patients with a variety of cancers. The
Company's research and development programs include growth factor
blockers and angiogenesis inhibitors. ImClone Systems' strategy is to
continue to grow into a fully integrated biopharmaceutical company,
taking its development programs from the research stage to clinical
impact, and, ultimately, commercialization. ImClone Systems'
headquarters and research operations are located in New York City,
with clinical, regulatory, medical affairs, commercial,
manufacturing, and additional administrative functions in Branchburg,
New Jersey.
Company: Locus Pharmaceuticals, Inc.
Investor Relations Contact: Robert Dickey IV, 215-358-2006
Web: www.locuspharma.com
Date of Presentation: 15-May-07
Locus is a world leader in computational drug design. The Company's
core technology is a fragment-based, computational approach, which
Locus has combined with highly integrated medicinal chemistry,
crystallography and biology capabilities to create a unique drug
design and development platform. Locus is using its capabilities to
develop its own compounds and has also entered into drug
design/development collaborations with pharmaceutical partners. All
of the Company's internal development programs emanate from its
computational technology and are focused on oral drug therapies,
principally in cancer and inflammation.
Company: LORUS THERAPEUTICS INC.
Ticker Symbol & Exchange: AMEX: LRP & TSX: LOR
Investor Relations Contact: Dr. Saeid Bababei, MBA., PhD., 416 798
1200 x 490
Web: www.lorusthera.com
Date of Presentation: 14-May-07
Lorus Therapeutics Inc. is a public Canadian biopharmaceutical Company
engaged in the discovery and development of innovative, effective and
safe products for the treatment of patients with cancer. Lorus' goal
is to capitalize on its research, preclinical, clinical and
regulatory expertise by developing new drug candidates that can be
used, either alone, or in combination, to successfully manage cancer.
Company: Maxygen, Inc.
Ticker Symbol & Exchange: Nasdaq: MAXY
Investor Relations Contact: Michele Boudreau, 650-279-2088
Web: www.maxygen.com
Date of Presentation: May 15, 11:10 am
Maxygen is a biopharmaceutical company focused on developing improved
versions of protein drugs. We look for opportunities where our
proprietary protein modification technologies can address significant
therapeutic needs. Products developed by Maxygen now in clinical
trials include a novel interferon-alpha for the treatment of
hepatitis C virus (HCV) infection and a novel G-CSF for the treatment
of neutropenia. Maxygen's approach may allow us to leverage the
established development and regulatory paths of approved drugs. We
believe this advantage translates to a greater chance of successfully
bringing important new drugs to market.
Company: Medgenics, Inc.
Investor Relations Contact: Andrew Pearlman, Phyllis Bellin; 972-4-
9588555, 972-54-2274827
Web: www.medgenics.com
Date of Presentation: May 15, 2007 , 3:15 pm, Atlantique Salon
Medgenics Inc. is a biopharmaceutical company developing a platform
technology to provide sustained-action protein therapy for the
treatment of a range of diseases, starting with anemia and hepatitis
C. Medgenics has already shown proof-of-principle of the Biopump to
deliver erythropoietin (EPO) in a clinical trial to anemic patients.
The Company is developing two products based on its sustained-action
Biopump technology: EPODURE producing EPO to treat anemia, and
INFRADURE producing interferon-alpha to treat hepatitis C. For more
information visit www.medgenics.com.
Company: MediGene AG
Ticker Symbol & Exchange: MDG
Investor Relations Contact: Dr. Michael Nettersheim,
investor@medigene.com, 49 - 89 - 85 65 -
2946
Web: www.medigene.com
Date of Presentation: May 15th 2007, 12:55 PM
MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG)
biotechnology company located in Martinsried/Munich, Germany, with
subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first
German biotech company with a drug on the market. A second drug has
been approved by the FDA. In addition, several drug candidates for
the treatment of cancer and autoimmune diseases are currently in
clinical development. MediGene also possesses innovative platform
technologies.
Company: Medivation, Inc.
Ticker Symbol & Exchange: Nasdaq: MDVN
Investor Relations Contact :Patrick Machado, 415-543-3470 (IR) or Jani
Bergan, 415-946-106 (PR)
Web: www.medivation.com
Date of Presentation: 14-May-07
Medivation, Inc. is a biopharmaceutical company with small molecule
drugs in development to treat three large, unmet medical needs -
Alzheimer's disease, Huntington's disease and hormone-refractory
prostate cancer. The Company intends to build and maintain a
portfolio of four to six development programs at all times.
Dimebon(TM), the Company's lead product candidate, is currently being
studied in clinical trials in patients with Alzheimer's disease and
Huntington's disease. Six-month results from a Phase 2 trial in
Alzheimer's disease demonstrated that Dimebon met all five efficacy
endpoints with strong statistical significance compared with placebo.
Company: Morria Biopharmaceuticals Plc
Investor Relations Contact: Yuval Cohen, 44 (0)207 152 6341
Web: www.morria.com
Date of Presentation: May 14th
Morria Biopharmaceuticals Plc. is a UK based drug development company
focused on novel anti-inflammatory drugs. Morria's lead products are
first-in-class, non-steroidal, synthetic anti-inflammatory drugs
termed Multi-Functional Anti-Inflammatory Drugs (MFAID). The company
has pre-clinical and clinical programs in dermatology, (contact
dermatitis), respiratory (allergic rhinitis and cystic fibrosis) and
gastro-intestinal inflammatory diseases (Inflammatory Bowel Disease).
Morria is also engaged in Discovery Partnerships with Big Pharma in
the fields of eyecare, ophthalmology and cardiovascular health.
Company: Neose Technologies, Inc.
Ticker Symbol & Exchange: Nasdaq GM: NTEC
Investor Relations Contact: Barbara Krauter, 215-315-9004
Web: www.neose.com
Date of Presentation: 15-May-07
Neose Technologies, Inc. is a clinical-stage biopharmaceutical company
focused on the development of next-generation therapeutic proteins
that are competitive with best-in-class protein drugs currently on
the market, on its own and through strategic partnerships. The lead
candidates in its pipeline, NE-180 for use in the treatment of
chemotherapy-induced anemia and anemia associated with chronic renal
failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia,
target markets with aggregate sales in excess of USD 15 billion. For
more information, please visit www.neose.com.
Company: NicOx
Ticker Symbol & Exchange: Euronext: NICOX
Investor Relations Contact :Karl Hanks; 33 (0)4 97 24 53 43;
hanks@nicox.com and Irene Lalande; 33
(0)4 97 24 53 11; lalande@nicox.com
Web: www.nicox.com
Date of Presentation: 15-May-07
NicOx is a product-driven biopharmaceutical company dedicated to the
development of nitric oxide-donating drugs to meet unmet medical
needs. NicOx is targeting the therapeutic areas of inflammatory and
cardio-metabolic diseases. Resources are focused on two lead
compounds, naproxcinod, in phase 3 development for the treatment of
osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes. NicOx
has strategic partnerships with some of the world's leading
pharmaceutical companies, including Pfizer Inc. and Merck and Co.,
Inc.
NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a
public company listed on the Eurolist of Euronext Paris (segment:
Next Economy).
Company: NovaDel Pharma
Ticker Symbol & Exchange: AMEX: NVD
Investor Relations Contact: Susan H. Griffin, 908-782-3431 ext. 2423,
sgriffin@novadel.com
Web: www.novadel.com
Date of Presentation: Tuesday, May 15, 2007 @ 11:10a.m.
NovaDel Pharma Inc. is a specialty pharmaceutical company developing
oral spray formulations of a broad range of marketed treatments. The
Company's proprietary oral spray technology offers the patient the
potential for (i) more rapid absorption of drugs to the bloodstream
compared to conventional oral dosage forms; (ii) limited first pass
liver metabolism; (iii) avoiding the need to swallow; (iv) allowing
medication to be taken without water; (v) improved drug safety
profile by reducing the required dosage; and (vi) improved patient
convenience and compliance. NovaDel's most advanced candidates target
nausea, insomnia, migraine headaches and disorders of the central
nervous system (CNS).
Company: Novelos Therapeutics, Inc.
Ticker Symbol & Exchange: OTCBB: NVLT
Investor Relations Contact: Stephen Lichaw, 201-240-3200
Web: www.novelos.com
Date of Presentation: May 14, 2007, 9:45am
Novelos Therapeutics, Inc. is a biopharmaceutical company
commercializing oxidized glutathione-based compounds for the
treatment of cancer and hepatitis. NOV-002, the lead compound
currently in Phase 3 development for lung cancer under a SPA and Fast
Track, acts together with chemotherapy as a chemoprotectant and an
immunomodulator. NOV-002 is also in Phase 2 development for
chemotherapy-resistant ovarian cancer and early-stage breast cancer,
and is in addition being developed for acute radiation injury. NOV-
205 acts as a hepatoprotective agent with immunomodulating and anti-
inflammatory properties. NOV-205 is in Phase 1b development for
chronic hepatitis C non-responders. Both compounds have completed
clinical trials in humans and have been approved for use in the
Russian Federation where they were originally developed.
Company: OMRIX Biopharmaceuticals, Inc.
Ticker Symbol & Exchange: NASDAQ: OMRI
Investor Relations Contact: Francesca DeMartino, 212-887-6510
Web: www.omrix.com
Date of Presentation: May 14, 2007; 9:45 AM (Local Time)
OMRIX is a profitable, fully-integrated biopharmaceutical company
developing and marketing protein-based biosurgery and passive
immunotherapy products. We utilize our proprietary protein
purification technology and manufacturing know-how to develop
products within our diversified and synergistic business platforms
and establish a presence in growing and under-penetrated markets. Our
biosurgery product line includes products and product candidates,
such as liquid fibrin sealants and thrombin products, used for the
control of bleeding, or hemostasis, and other surgical applications.
Our passive immunotherapy product line includes antibody-rich
products and product candidates for the treatment of immune
deficiencies, infectious diseases and potential biodefense
applications.
Company: Orexo AB
Ticker Symbol & Exchange: ORX (SSE)
Investor Relations Contact: Mr Claes Wenthzel, Executive Vice
President & CEO, 46 18 780 88 00
Web: www.orexo.com
Date of Presentation: 15-May-07
Orexo AB is a pharmaceutical company developing new pharmaceutical
drugs within areas currently subject to considerable unmet medical
needs. Orexo applies its broad expertise in medicine and
pharmaceuticals to the further development of existing pharmaceutical
substances. By combining well-documented compounds with its own
patented drug delivery methods and its unique expertise in "dry
formulations" (for example, tablets), Orexo is able to develop new
patented pharmaceuticals.
Orexo has grown into an organization with 67 full-time employees, most
of whom are active in research and development, clinical development
and pharmaceutical registration. At present, the company has two
products on the market, three products in late clinical development
phase - one of which has been out-licensed in the US, Europe and
Japan and submitted for registration in Europe - and two projects in
pharmaceutical formulation phase. Orexo has adopted an active
intellectual property rights strategy and has, since its inception,
built up an extensive patent portfolio to protect its products and
technologies.
Company: PAION AG
Ticker Symbol & Exchange: PA8, Frankfurt Stock Exchange
Investor Relations Contact: Dr. Peer Nils Schroeder, 49-241-4453-152
Web: www.paion.de
Date of Presentation: 14-May-07
PAION, a biopharmaceutical company based in Aachen, Germany, aims to
become a leader in developing and commercialising innovative drugs
for the treatment of stroke and other thrombotic diseases for which
there is a substantial unmet medical need. PAION intends to build an
integrated drug portfolio by exploiting its expertise in identifying
compounds, licensing or otherwise acquiring them and advancing them
through the clinical development and regulatory approval process.
Results for the Phase III study of PAION's lead product Desmoteplase
will be presented 1 June 2007. In 2006, PAION employed on average 77
people.
Company: Pipex Pharmaceuticals, Inc.
Ticker Symbol & Exchange: PPXP (OTCBB)
Investor Relations Contact: Thomas Redington, 203-222-7399
Web: www.pipexpharma.com
Date of Presentation: 5/15/2007
Pipex Pharmaceuticals, Inc. is a specialty pharmaceutical company that
is developing proprietary, late-stage drug candidates for the
treatment of neurologic and fibrotic diseases. Pipex's lead product,
COPREXA(TM) (oral tetrathiomolybdate) has completed pivotal clinical
trials for an orphan genetic disease, known as neurologic Wilson's
disease and has also completed phase II clinical trials for
Idiopathic Pulmonary Fibrosis (IPF), a deadly lung disease.
Pipex is also developing TRIMESTA(TM) (oral estriol) for the treatment
of multiple sclerosis which has completed a phase II clinical trial.
For further information, please visit, www.pipexpharma.com.
Company: Prana Biotechnology Ltd.
Ticker Symbol & Exchange: PRAN: NASDAQ / PBT: ASX (Australia)
Investor Relations Contact: Kathy Price, 646-284-9430
Web: www.pranabio.com
Date of Presentation: 15-May-07
Prana Biotechnology Ltd. is a biopharmaceutical company focused on the
research and development of treatments for Alzheimer's disease and
other age-related neurodegenerative disorders. Prana's discoveries,
emerging out of Massachusetts General Hospital at Harvard University
and the University of Melbourne in Australia, have lead to the
development of MPAC's (Metal Protein Attenuating Compounds). MPAC's
have shown great promise to treat a variety of neurodegenerative
disorders. Clinical efficacy (phase 2) has earlier been demonstrated
in a 'proof of principle' MPAC (PBT1) for Alzheimer's disease.
Prana's lead proprietary molecule, PBT2, is currently in Phase IIa
testing for Alzheimer's disease.
Company: ProMetic Life Sciences Inc.
Ticker Symbol & Exchange: PLI (TSX)
Investor Relations Contact: Lippert/Heilshorn & Associates, Inc, Lisa
Lindberg, (212) 838-3777
Web: www.prometic.com
Date of Presentation: May 15, 2007 - 3:15pm
ProMetic Life Sciences Inc. is a biopharmaceutical company specialized
in the research, development, manufacture and marketing of a variety
of commercial applications derived from its proprietary Mimetic
Ligand(TM) enabling technology. This technology is used in large-
scale purification of biologics and the elimination of pathogens.
ProMetic is also active in therapeutic drug development with the
mission to bring to market effective, innovative, lower cost, less
toxic products for the treatment of inflammation and cancer. Its drug
discovery platform is focused on replacing complex, expensive
proteins with synthetic "drug-like" protein mimetics. Headquartered
in Montreal, Canada, ProMetic has R&D and manufacturing facilities in
the UK and business development activities in the US, Europe, Asia
and MENA countries (Middle East and North Africa).
Company: Protherics PLC
Ticker Symbol & Exchange: LSE: PTI, NASDAQ: PTIL
Investor Relations Contact: Nick Staples, 44 (0)20 7246 9950 or 44
(0)7919 480 510
Web: www.protherics.com
Date of Presentation: 10.50am Tuesday 15 May
Protherics PLC is a leading biopharmaceutical company focused on the
development, manufacture and marketing of specialised products for
critical care and cancer.
Protherics has developed and manufactures two biologics for critical
care which are FDA approved and currently sold in the US: CroFab(TM),
a pit viper antivenom and DigiFab(TM), a digoxin antidote. The
Company's strategy is to use the revenues generated from its marketed
and out-licensed products to help fund the advancement of its broad,
late stage pipeline.
Protherics has two major development opportunities in its critical
care portfolio. CytoFab(TM) is being developed by AstraZeneca for the
treatment of severe sepsis and Digoxin Immune Fabs for the treatment
of pre-eclampsia. Protherics also has a pipeline of four novel cancer
products in clinical development.
With headquarters in London, the Company has approximately 260
employees in the UK, US and Australia. For further information please
visit www.protherics.com
Company: Starpharma Holdings Limited
Ticker Symbol & Exchange: ASX:SPL, OTCQX: SPHRY
Investor Relations Contact: Jennifer K. Zimmons, Ph.D.; 212-838-1444
or Dr Jackie Fairley, CEO; 61 3 8532
2704, 61 407 716 887 (Cell)
Web: www.starpharma.com
Date of Presentation: Tuesday May 15, 2007 - 9:45am
Starpharma is pioneering the development of dendrimer nanotechnology
products for pharmaceutical, life science, and other applications.
Lead product, VivaGel(TM), is a vaginal microbicide designed to
prevent the transmission of Sexually Transmitted Infections
(specifically HIV and genital herpes). Currently in human clinical
trials, VivaGel(TM) has received US FDA Fast Track status and more
than USD 20M in non-dilutive support from the NIH. VivaGel(TM)
addresses multi-billion dollar markets aimed at preventing sexually
transmitted infections. The product has also shown activity as a
contraceptive and the active ingredient has potential application as
a condom coating agent.
Through the 2006 acquisition of US-based Dendritic Nanotechnologies,
Starpharma has expanded its product pipeline to include drug
delivery, siRNA transfection and industrial chemical applications.
Through DNT the company has royalty-bearing relationships with Dade
Behring, Qiagen, Sigma, Aldrich and EMD Biosciences.
With an active American Depositary Receipts (ADR) program
(OTCQX:SPHRY) in place, Dow Chemical (NASDQ:DOW) as lead shareholder,
and US offices, Starpharma is actively embracing the US market.
Currently more than 20% of Starpharma's shares are held by US
investors, with DOW holding 8.6%.
Company: Tercica, Inc.
Ticker Symbol & Exchange: Nasdaq: TRCA
Investor Relations Contact: Fredrik Wiklund, 650-624-4992
Web: www.tercica.com
Date of Presentation: 5/14/07 at 9:00 a.m. local time
Tercica is a biopharmaceutical company committed to improving
endocrine health by partnering with the endocrine community to
develop and commercialize new therapeutics for short stature and
other metabolic disorders. For further information on Tercica, please
visit www.tercica.com.
Company: UTEK Corporation
Ticker Symbol & Exchange: AMEX: UTK and LSE-AIM: UTK
Investor Relations Contact: Steve Liebmann or Simon Bloomfield, 44 (0)
20-7367-8883
Web: www.utekcorp.com
Date of Presentation: Monday, May 14, 2007
UTEK(R) is a specialty finance company focused on technology transfer.
UTEK's services enable companies to rapidly acquire innovative
technologies from universities and research laboratories worldwide in
exchange for their equity securities. This unique process is called
U2B(R). In addition, UTEK offers companies the tools to search, and
analyze intellectual properties. UTEK is a business development
company with operations in the United States, United Kingdom and
Israel.
Company: ViroPharma Incorporated
Ticker Symbol & Exchange: Nasdaq: VPHM
Investor Relations Contact: Will Roberts, 610-321-6288
Web: www.viropharma.com
Date of Presentation: 5/14/2007
ViroPharma Incorporated is committed to the development and
commercialization of products that address serious diseases treated
by physician specialists and in hospital settings. ViroPharma
commercializes Vancocin(R) approved for oral administration for
treatment of antibiotic-associated pseudomembranous colitis caused by
Clostridium difficile and enterocolitis caused by Staphylococcus
aureus, including methicillin-resistant strains (for prescribing
information, please download the package insert at
http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma
currently focuses its drug development activities in viral diseases
including cytomegalovirus (CMV) and hepatitis C virus (HCV).
Company: XYTIS
Investor Relations Contact: Vincent F. Simmon, Chairman, President &
CEO, 949 226 1118
Web: www.xytis.com
Date of Presentation: May 14th 2007 at 9:45AM
Xytis is a CNS small molecule private company formed in 2005 by the
merger of Xytis Pharmaceuticals Ltd. and Remergent Inc. Current
investors are Atlas Venture, Sanderling, CDC Entreprises, and
Ventech. Xytis pipeline includes two compounds in the clinic. XY2405,
an inhibitor of Bradykinin B2 receptor, is in PhII trial for
Traumatic Brain Injury. XY2401, currently in PhIb, is an anti-
psychotic agent that was shown to improve cognitive performance and
revealed anxiolytic and anti-depressive activity in animal models. In
addition, Xytis has a rich portfolio of preclinical compounds that
are highly selective positive allosteric modulators of nicotinic
Acetylcholine and GABAA receptors being readied for IND filing.
Company: ZIOPHARM Oncology, Inc.
Ticker Symbol & Exchange: ZIOP: NASDAQ
Investor Relations Contact: Suzanne McKenna, 646-214-0703
Web: www.ziopharm.com
Date of Presentation: 15-May-07
ZIOPHARM Oncology is a biopharmaceutical company engaged in the
development and commercialization of a diverse, risk-sensitive
portfolio of in-licensed cancer drugs to address unmet medical needs.
The Company applies new insights from molecular and cancer biology to
understand the efficacy and safety limitations of approved and
developmental cancer therapies and identifies proprietary and related
molecules for better patient treatment.
*T
Note to Editors: Business Wire's PressPass allows you to create
free, custom Web, RSS, and email-based news feeds from more than 160
industry options, dozens of subject categories and thousands of
geographic preferences as well as by specific company filters. In
addition, PressPass subscribers have access to exclusive content,
experts, company profiles, email alerts, survey services and other
media services.
Note to Event Organizers: Add your trade show, conference, or
event to http://www.tradeshownews.com, Business Wire's online event
calendar. For information, email tradeshow@businesswire.com.
